REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)
Status: Recruiting
Location: See all (64) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Confirmed Multiple Sclerosis (MS) diagnosis.
• Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included.
Locations
United States
Alabama
TG Therapeutics Investigational Trial Site
RECRUITING
Birmingham
Arizona
TG Therapeutics Investigational Trial Site
RECRUITING
Gilbert
TG Therapeutics Investigational Trial Site
RECRUITING
Phoenix
California
TG Therapeutics Investigational Trial Site
RECRUITING
Newport Beach
TG Therapeutics Investigational Trial Site
RECRUITING
Orange
Colorado
TG Therapeutics Investigational Trial Site
RECRUITING
Aurora
TG Therapeutics Investigational Trial Site
RECRUITING
Basalt
TG Therapeutics Investigational Trial Site
RECRUITING
Colorado Springs
TG Therapeutics Investigational Trial Site
RECRUITING
Denver
TG Therapeutics Investigational Trial Site
RECRUITING
Fort Collins
Connecticut
TG Therapeutics Investigational Trial Site
RECRUITING
Farmington
TG Therapeutics Investigational Trial Site
RECRUITING
Hartford
Washington, D.c.
TG Therapeutics Investigational Trial Site
RECRUITING
Washington D.c.
Florida
TG Therapeutics Investigational Trial Site
RECRUITING
Altamonte Springs
TG Therapeutics Investigational Trial Site
RECRUITING
Boca Raton
TG Therapeutics Investigational Trial Site
RECRUITING
Clearwater
TG Therapeutics Investigational Trial Site
RECRUITING
Maitland
TG Therapeutics Investigational Trial Site
RECRUITING
Naples
Georgia
TG Therapeutics Investigational Trial Site
RECRUITING
Atlanta
TG Therapeutics Investigational Trial Site
RECRUITING
Atlanta
Idaho
TG Therapeutics Investigational Trial Site
RECRUITING
Coeur D'alene
Illinois
TG Therapeutics Investigational Trial Site
RECRUITING
Chicago
TG Therapeutics Investigational Trial Site
RECRUITING
Evanston
TG Therapeutics Investigational Trial Site
RECRUITING
Urbana
Kentucky
TG Therapeutics Investigational Trial Site
RECRUITING
Lexington
TG Therapeutics Investigational Trial Site
RECRUITING
Louisville
Massachusetts
TG Therapeutics Investigational Trial Site
RECRUITING
Burlington
TG Therapeutics Investigational Trial Site
RECRUITING
Norfolk
Maryland
TG Therapeutics Investigational Trial Site
RECRUITING
Baltimore
TG Therapeutics Investigational Trial Site
RECRUITING
Glen Burnie
Michigan
TG Therapeutics Investigational Trial Site
RECRUITING
Ann Arbor
TG Therapeutics Investigational Trial Site
RECRUITING
Farmington
TG Therapeutics Investigational Trial Site
RECRUITING
Owosso
North Carolina
TG Therapeutics Investigational Trial Site
RECRUITING
Charlotte
TG Therapeutics Investigational Trial Site
RECRUITING
Raleigh
Nebraska
TG Therapeutics Investigational Trial Site
RECRUITING
Omaha
New Jersey
TG Therapeutics Investigational Trial Site
RECRUITING
Livingston
TG Therapeutics Investigational Trial Site
RECRUITING
Neptune City
TG Therapeutics Investigational Trial Site
RECRUITING
Teaneck
Nevada
TG Therapeutics Investigational Trial Site
RECRUITING
Las Vegas
New York
TG Therapeutics Investigational Trial Site
RECRUITING
Amherst
TG Therapeutics Investigational Trial Site
RECRUITING
New York
Ohio
TG Therapeutics Investigational Trial Site
RECRUITING
Centerville
TG Therapeutics Investigational Trial Site
RECRUITING
Centerville
TG Therapeutics Investigational Trial Site
RECRUITING
Cincinnati
TG Therapeutics Investigational Trial Site
RECRUITING
Cleveland
TG Therapeutics Investigational Trial Site
RECRUITING
Columbus
TG Therapeutics Investigational Trial Site
RECRUITING
Toledo
Oregon
TG Therapeutics Investigational Trial Site
RECRUITING
Portland
Tennessee
TG Therapeutics Investigational Trial Site
RECRUITING
Knoxville
TG Therapeutics Investigational Trial Site
RECRUITING
Nashville
Texas
TG Therapeutics Investigational Trial Site
RECRUITING
Austin
TG Therapeutics Investigational Trial Site
RECRUITING
Austin
TG Therapeutics Investigational Trial Site
RECRUITING
Austin
TG Therapeutics Investigational Trial Site
RECRUITING
Dallas
TG Therapeutics Investigational Trial Site
RECRUITING
San Antonio
Virginia
TG Therapeutics Investigational Trial Site
RECRUITING
Norfolk
TG Therapeutics Investigational Trial Site
RECRUITING
Vienna
Washington
TG Therapeutics Investigational Trial Site
RECRUITING
Kirkland
Wisconsin
TG Therapeutics Investigational Trial Site
RECRUITING
Greenfield
TG Therapeutics Investigational Trial Site
RECRUITING
Milwaukee
TG Therapeutics Investigational Trial Site
RECRUITING
Neenah
TG Therapeutics Investigational Trial Site
RECRUITING
Waukesha
Other Locations
Puerto Rico
TG Therapeutics Investigational Trial Site
RECRUITING
Guaynabo
Contact Information
Primary
TG Therapeutics Clinical Support Team
clinicalsupport@tgtxinc.com
1-877-575-8489
Time Frame
Start Date: 2024-07-22
Estimated Completion Date: 2027-07-01
Participants
Target number of participants: 500
Treatments
BRIUMVI® (Ublituximab-xiiy)
Participants will receive BRIUMVI® (Ublituximab-xiiy) intravenous (IV) infusion for the treatment of RMS.
Related Therapeutic Areas
Sponsors
Leads: TG Therapeutics, Inc.